Skip to main content
Erschienen in: International Journal of Clinical Pharmacy 5/2019

28.09.2019 | Research Article

Experience with a colorectal cancer campaign in Swiss pharmacies

verfasst von: Martine Ruggli, Daniela Stebler, Markus Gasteiger, Maria Trottmann, Philip Hochuli, Harry Telser, Fabian Vaucher

Erschienen in: International Journal of Clinical Pharmacy | Ausgabe 5/2019

Einloggen, um Zugang zu erhalten

Abstract

Background Colorectal cancer is the third most common cancer worldwide. Screening with several methods can accurately detect early-stage cancer and polyps and reduce colorectal cancer mortality in adults aged 50 to 75 years. Objective Test the feasibility, interest and potential impact of a colorectal cancer screening in Swiss community pharmacies. Setting 771 community pharmacies of Switzerland participated in a 6-week campaign. Method The pharmacists evaluated the risk factors through a questionnaire among individuals aged between 50 to 75 years old who did not have had a colonoscopy over the previous 10 years. Pharmacists delivered a Faecal Immunochemical Test (FIT) to those without risk. Patients with identified risk factors or with a positive result were referred to a physician. Patients with a negative result were given lifestyle advice and invited for a new screening in two years. Main outcome measure The impact was measured through the number of persons screened, of tests delivered and of referrals to a physician performed. Results Within 6 weeks, 23,024 persons were screened in pharmacies. In total, 760 patients (3%) had risk factors and were directly referred to physicians. The remaining 22,264 received a FIT, and 97% of these individuals performed and sent the FIT to the laboratory. Of the 21,701 tests analysed, 93% were negative. All individuals with positive results (7%) were referred to a physician. Conclusion Having the opportunity to take colorectal cancer prevention measures with a low threshold, like in a community pharmacy encourages the population to perform the screening.
Literatur
1.
Zurück zum Zitat Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, et al. GLOBOCAN 2012v1.0 Cancer Incidence and Mortality Worldwide: IARC Cancerbase No 11. International Agency for Research on Cancer; 2013 [cited 01 March 2019]. Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, et al. GLOBOCAN 2012v1.0 Cancer Incidence and Mortality Worldwide: IARC Cancerbase No 11. International Agency for Research on Cancer; 2013 [cited 01 March 2019].
2.
Zurück zum Zitat NICER (National Institute for Cancer Epidemiology and Registration) and Federal office of statistics. Schweizerischer Krebsbericht, 2015 Stand und Entwicklung [Swiss cancer report, 2015: state and development]. Zurich: National Institute for Cancer Epidemiology and Registration (CH); 2016 [cited 01 March 2019]. NICER (National Institute for Cancer Epidemiology and Registration) and Federal office of statistics. Schweizerischer Krebsbericht, 2015 Stand und Entwicklung [Swiss cancer report, 2015: state and development]. Zurich: National Institute for Cancer Epidemiology and Registration (CH); 2016 [cited 01 March 2019].
3.
Zurück zum Zitat Bacchus CM, Dunfield L, Gorber SC, Holmes NM, Birtwhistle R, Dickinson JA, et al. Canadian task force on preventive health care. Recommendations on screening for colorectal cancer in primary care. CMAJ. 2016;188:340–8.CrossRef Bacchus CM, Dunfield L, Gorber SC, Holmes NM, Birtwhistle R, Dickinson JA, et al. Canadian task force on preventive health care. Recommendations on screening for colorectal cancer in primary care. CMAJ. 2016;188:340–8.CrossRef
4.
Zurück zum Zitat Holme Ø, Bretthauer M, Fretheim A, Odgaard-Jense J, Hoff G. Flexible sigmoidoscopy versus faecal occult blood testing for colorectal cancer screening in asymptomatic individuals. Cochrane Database Syst Rev. 2013;9:CD009259. Holme Ø, Bretthauer M, Fretheim A, Odgaard-Jense J, Hoff G. Flexible sigmoidoscopy versus faecal occult blood testing for colorectal cancer screening in asymptomatic individuals. Cochrane Database Syst Rev. 2013;9:CD009259.
5.
Zurück zum Zitat Quintero E, Castells A, Bujanda L, Cubiella J, Salas D, Lanas Á, González-Navarro A. Colonoscopy versus fecal immunochemical testing in colorectal-cancer screening. N Engl J Med. 2012;366(8):697–706.CrossRef Quintero E, Castells A, Bujanda L, Cubiella J, Salas D, Lanas Á, González-Navarro A. Colonoscopy versus fecal immunochemical testing in colorectal-cancer screening. N Engl J Med. 2012;366(8):697–706.CrossRef
6.
Zurück zum Zitat Lin J, Piper M, Perdue L, Rutter C, Webber E, O’Connor E, et al. Screening for colorectal cancer: a systematic review for the U.S. preventive services task force. Evidence Synthesis No. 135. AHRQ Publication No. 14-05203-EF-1. Rockville, MD: Agency for Healthcare Research and Quality; 2016. Lin J, Piper M, Perdue L, Rutter C, Webber E, O’Connor E, et al. Screening for colorectal cancer: a systematic review for the U.S. preventive services task force. Evidence Synthesis No. 135. AHRQ Publication No. 14-05203-EF-1. Rockville, MD: Agency for Healthcare Research and Quality; 2016.
7.
Zurück zum Zitat Labianca R, Nordlinger B, Beretta GD, Mosconi S, Mandalà M, Cervantes A, Arnold D, ESMO Guidelines Working Group. Early colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013;24(Suppl 6):vi64–vi72.CrossRef Labianca R, Nordlinger B, Beretta GD, Mosconi S, Mandalà M, Cervantes A, Arnold D, ESMO Guidelines Working Group. Early colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013;24(Suppl 6):vi64–vi72.CrossRef
9.
Zurück zum Zitat Kramis K, Ruckstuhl B, Wyler M. Nationale Strategie gegen Krebs 2014–2017 [National strategy against cancer report]; Bern: Federal Office of Public Health FOPH (CH); 2013 [cited 01 March 2019]. Kramis K, Ruckstuhl B, Wyler M. Nationale Strategie gegen Krebs 2014–2017 [National strategy against cancer report]; Bern: Federal Office of Public Health FOPH (CH); 2013 [cited 01 March 2019].
10.
Zurück zum Zitat Federal Department of Home Affairs FDHA. Verordnung des EDI über Leistungen in der obligatorischen Krankenpflegeversicherung [Implementation regulation on mandatory health insurance services, Federal Office of Health]. Bern: Federal Council (CH); [cited 01 March 2019]. Federal Department of Home Affairs FDHA. Verordnung des EDI über Leistungen in der obligatorischen Krankenpflegeversicherung [Implementation regulation on mandatory health insurance services, Federal Office of Health]. Bern: Federal Council (CH); [cited 01 March 2019].
11.
Zurück zum Zitat Fedewa S, Cullati S, Bouchardy C, Welle I, Burton-Jeangros C, Manor O, Guessous I. Colorectal cancer screening in Switzerland: cross-sectional trends (2007–2012) in socioeconomic disparities. PLoS ONE. 2015;10(7):e0131205–e01312050131205.CrossRef Fedewa S, Cullati S, Bouchardy C, Welle I, Burton-Jeangros C, Manor O, Guessous I. Colorectal cancer screening in Switzerland: cross-sectional trends (2007–2012) in socioeconomic disparities. PLoS ONE. 2015;10(7):e0131205–e01312050131205.CrossRef
12.
Zurück zum Zitat Federal Council of Switzerland. Bericht des Bundesrates in Erfüllung des Postulats Humbel (Nr. 12.3864) vom 27. September 2012: Positionierung der Apotheken in der Grundversorgung [Swiss Federal’s Council’s report in response to the postulate Humbel (12.3864) dated 27 September 2012; Positioning of pharmacies in primary care]. Bern: Federal Council (CH); 2016 [cited 01 March 2019]. Federal Council of Switzerland. Bericht des Bundesrates in Erfüllung des Postulats Humbel (Nr. 12.3864) vom 27. September 2012: Positionierung der Apotheken in der Grundversorgung [Swiss Federal’s Council’s report in response to the postulate Humbel (12.3864) dated 27 September 2012; Positioning of pharmacies in primary care]. Bern: Federal Council (CH); 2016 [cited 01 March 2019].
13.
Zurück zum Zitat Hol L, Wilschut JA, van Ballegooijen M, van Vuuren AJ, van der Valk H, Reijerink J, van der Togt ACM, Kuipers EJ, Habbema JDF, van Leerdam ME. Screening for colorectal cancer: random comparison of guaiac and immunochemical faecal occult blood testing at different cut-off levels. Br J Cancer. 2009;100(7):1103–10.CrossRef Hol L, Wilschut JA, van Ballegooijen M, van Vuuren AJ, van der Valk H, Reijerink J, van der Togt ACM, Kuipers EJ, Habbema JDF, van Leerdam ME. Screening for colorectal cancer: random comparison of guaiac and immunochemical faecal occult blood testing at different cut-off levels. Br J Cancer. 2009;100(7):1103–10.CrossRef
14.
Zurück zum Zitat Marbet U, Bauerfeind P, Brunner J, Dorta G, Valloton J, Delcò F. Colonoscopy is the preferred colorectal cancer screening method in a population-based program. Endoscopy. 2008;40(08):650–5.CrossRef Marbet U, Bauerfeind P, Brunner J, Dorta G, Valloton J, Delcò F. Colonoscopy is the preferred colorectal cancer screening method in a population-based program. Endoscopy. 2008;40(08):650–5.CrossRef
15.
Zurück zum Zitat Denters MJ, Deutekom M, Bossuyt PM, Stroobants AK, Fockens P, Dekker E. Lower risk of advanced neoplasia among patients with a previous negative result from a fecal test for colorectal cancer. Gastroenterology. 2012;142(3):497–504.CrossRef Denters MJ, Deutekom M, Bossuyt PM, Stroobants AK, Fockens P, Dekker E. Lower risk of advanced neoplasia among patients with a previous negative result from a fecal test for colorectal cancer. Gastroenterology. 2012;142(3):497–504.CrossRef
16.
Zurück zum Zitat Selby K, Baumgartner C, Levin TR, Doueni CA, Zauber AG, Scottinger J, Jensen CD, Lee JK, Corley A. Interventions to improve follow-up of positive results on fecal blood tests a systematic review. Ann Intern Med. 2017;167:565–75.CrossRef Selby K, Baumgartner C, Levin TR, Doueni CA, Zauber AG, Scottinger J, Jensen CD, Lee JK, Corley A. Interventions to improve follow-up of positive results on fecal blood tests a systematic review. Ann Intern Med. 2017;167:565–75.CrossRef
17.
Zurück zum Zitat von Karsa L, Patnick J, Segnan N, Atkin W, Halloran S, Lansdorp-Vogelaar I, et al. European guidelines for quality assurance in colorectal cancer screening and diagnosis: overview and introduction to the full supplement publication. Endoscopy. 2013;45(1):51–9. von Karsa L, Patnick J, Segnan N, Atkin W, Halloran S, Lansdorp-Vogelaar I, et al. European guidelines for quality assurance in colorectal cancer screening and diagnosis: overview and introduction to the full supplement publication. Endoscopy. 2013;45(1):51–9.
18.
Zurück zum Zitat Inadomi JM. Screening for colorectal neoplasia. N Engl J Med. 2017;376:149–56.CrossRef Inadomi JM. Screening for colorectal neoplasia. N Engl J Med. 2017;376:149–56.CrossRef
Metadaten
Titel
Experience with a colorectal cancer campaign in Swiss pharmacies
verfasst von
Martine Ruggli
Daniela Stebler
Markus Gasteiger
Maria Trottmann
Philip Hochuli
Harry Telser
Fabian Vaucher
Publikationsdatum
28.09.2019
Verlag
Springer International Publishing
Erschienen in
International Journal of Clinical Pharmacy / Ausgabe 5/2019
Print ISSN: 2210-7703
Elektronische ISSN: 2210-7711
DOI
https://doi.org/10.1007/s11096-019-00899-z

Weitere Artikel der Ausgabe 5/2019

International Journal of Clinical Pharmacy 5/2019 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.